<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38428">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01814722</url>
  </required_header>
  <id_info>
    <org_study_id>0518-266</org_study_id>
    <nct_id>NCT01814722</nct_id>
  </id_info>
  <brief_title>Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)</brief_title>
  <official_title>Quality of Life of HIV-infected Patients Switched to Raltegravir Versus Other Antiretroviral Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, longitudinal observational study of adult human immunodeficiency
      virus (HIV) participants at academic and community-based practices in the United States who
      are switching from first-line to second-line therapy. The study's primary hypothesis is that
      HIV participants switching to raltegravir-based regimens will have better Medical Outcomes
      Study-HIV (MOS-HIV) Health Survey scores than participants switched to non-nucleoside
      reverse transcriptase inhibitor (NNRTI)-based or protease inhibitor (PI)-based regimens.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Comparison of Medical Outcomes Study-HIV (MOS-HIV) Health Survey Scores</measure>
    <time_frame>Week 4 Follow-up</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Depression, Anxiety, and Stress Scale (DASS-21)</measure>
    <time_frame>Baseline and Week 4 Follow-up</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in HIV Symptom Index (HIV-SI)</measure>
    <time_frame>Baseline and Week 4 Follow-up</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>Baseline and Week 4 Follow-up</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">134</enrollment>
  <condition>Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>Raltegravir + 2 NRTIs</arm_group_label>
    <description>Raltegravir is an integrase inhibitor.
Nucleoside Reverse Transcriptase Inhibitor (NRTIs)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NNRTI + 2 NRTIs</arm_group_label>
    <description>Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) could include: delavirdine, efavirenz, etravirine, rilpivirine, nevirapine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PI + 2 NRTIs</arm_group_label>
    <description>Protease inhibitors (PI) could include: nelfinavir, lopinavir, saquinavir, tipranavir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Other Second Line Therapies</arm_group_label>
    <description>Other second line therapies could include: enfuvirtide, maraviroc, raltegravir + PI</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        HIV patients at academic and community-based practices in the United States
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of HIV

          -  Switching antiretroviral regimen(s) for the first time at the start of the study

        Exclusion Criteria:

          -  Currently pregnant

          -  Presence of active tuberculosis, Hepatitis B, and/or Hepatitis C and receiving
             treatment for the condition(s) during the study period

          -  Presence of active pneumonia or other signs of opportunistic infections at the start
             of the study

          -  Currently participating in a clinical trial
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 19, 2013</lastchanged_date>
  <firstreceived_date>March 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV Infections</keyword>
  <keyword>Anti-HIV Agents</keyword>
  <keyword>Anti-Retroviral Agents</keyword>
  <keyword>Nucleoside Reverse Transcriptase Inhibitors</keyword>
  <keyword>Non-nucleoside Reverse Transcriptase Inhibitor</keyword>
  <keyword>Protease inhibitors</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Protease Inhibitors</mesh_term>
    <mesh_term>HIV Protease Inhibitors</mesh_term>
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
    <mesh_term>Anti-Retroviral Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
